Cambridge, UK; 21st August, 2020.

Atlantic Healthcare plc (“Atlantic Healthcare” or “Company”) is pleased to have been invited to present at the forthcoming Lingmed Chinese forum ‘Innovation for digestive diseases treatment? China market and Global market deep dive, are you ready?’

Each month this forum focusses on a specific therapy area with a guest speaker from Europe invited to present. This month the event will take place on Friday 28th August and Toby Wilson Waterworth has been invited to present Atlantic Healthcare and its portfolio together with its plans to enter the Chinese market through a partner.

The August forum will be hosted by Lingmed CEO Lingling Cao (whose extensive expertise includes senior BD manager for Eli Lilly in Shanghai and a consultant for McKinsey in Germany) and Dr Hank Wang Lingmed’s Medical Advisor (previously Vice President and President of R&D at Beijing Haiyan Pharmaceutical Co., Ltd.).

Atlantic Healthcare has engaged Linkedbio Partnering, a partnering service provided by Lingmed, to assist in the search for a partner whom can work with Atlantic in finalising the development and commercialisation of its products over the coming years.

The forum, which is conducted in Chinese and English, is on Friday 28th August, 10am-11am Berlin time. If you would like to attend, please register by clicking here.

Toby Wilson Waterworth, CEO of Atlantic Healthcare said: “Our global plans for Atlantic Healthcare take another significant step forward with this arrangement, and we are delighted to be chosen as a thought leader and influencer in the area of GI development at Lingmed’s forum. By working with local players in China and South East Asia we are looking to develop long-standing relationships to support our mutual growth plans.” 

About Atlantic Healthcare

Atlantic Healthcare plc ( is a specialist pharmaceutical company focused on acquiring, developing and commercializing therapeutics that address unmet patient needs and rare diseases.

 The Company owns the exclusive worldwide rights to alicaforsen, a novel antisense drug in development for ulcerative colitis and Crohn’s disease, and renzapride, which has the potential to address the unmet needs of multiple patient groups suffering gastrointestinal motility disorders.  This includes constipation predominant Irritable Bowel Syndrome (IBS-c) and motility problems experienced by Cystic Fibrosis and Systemic Scleroderma patients.

Led by an experienced international Board and Leadership Team who have deep roots and a proven track record in the pharmaceutical industry, Atlantic Healthcare plans to commercialize its products itself in the U.S. and Europe and through partnerships and licensing with established pharmaceutical companies in the rest of the world.

Forward Looking Statements

While Atlantic Healthcare believes any forward-looking statements in this press release are accurate, the statements represent Atlantic Healthcare’s beliefs only as of the date of this press release. A number of factors could cause actual events or results to differ materially from those indicated by such statements. These forward-looking statements involve risks and uncertainties. In addition, risks and results in clinical trials may not be indicative of risks or results from later stage or larger scale trials, and there is no assurance of regulatory approval. Existing and prospective investors should not place undue reliance on the forward-looking statements contained in a press release and instead should make their own determinations as to the reliability of such statements. Atlantic Healthcare undertakes no intent or obligation to update the information contained in this press release as new information becomes available.

For more information about Atlantic Healthcare, investment, alicaforsen or renzapride, please contact:

Adam Michael (Head of Communications)

+44 1799 512 055

+44 777 588 1813

About Lingmed

Lingmed Ltd ( is a young, professional and fast growing company promoting world best-in-class intelligence databases to the healthcare industry and providing its premium services – Linkedbio – analytical and partnering support to help Biotech companies to identify and partner into the Chinese market.